At the intersection of strategy and logistics, accurate demand forecasting remains one of the most critical—and complex—challenges in clinical supply. Thought leaders tackled one big question: how can sponsors and supply teams optimize Interactive Response Technology (IRT) settings and demand forecasts in increasingly unpredictable environments?

The key takeaway? It’s time to treat forecasting as a living, breathing process—not a one-time spreadsheet exercise.

When it comes to getting investigational product to patients—on time and in spec—the Qualified Person (QP) is a non-negotiable asset. Acting as the final gatekeeper before release, the QP holds the line between regulatory compliance and costly disruption.

Getting product out the door isn’t the goal—getting it to site, on time, and without risk is. And when it comes to exporting investigational medicines, success hinges less on logistics and more on foresight.

Clinical exports are often treated like a downstream task. In reality, they’re a risk vector that can derail entire trial timelines if not planned with precision.

Importing clinical trial materials sounds simple—until it isn’t. The paperwork doesn’t line up. A comparator gets flagged. A country requires a license you didn’t know existed. Suddenly, your first-patient-in date is at risk because a shipment is stuck at the border.

Here’s the reality: importing investigational products (IP) is not an afterthought. It’s a strategic function that, if neglected, can quietly jeopardize your entire trial.